drugset / Trial / NCT04325802

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802

Phase 2 Withdrawn University of Minnesota
RandomizedCrossoverQuadruple-blindTreatment

Summary

Purpose: To study the etiology and the epigenetic pathways leading to and regulating chronic itch. Similarly, to examine the mechanisms underlying skin changes, including epigenetic alterations while also testing the efficacy of opioid antagonists in atopic dermatitis. In this study, the investigators aim to examine chronic sensory disorder mechanisms related to chronic itch.

Timeline

Start
2022-12-31
Primary completion
2024-06
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 50 mg

Indications